“…However, the approach can be further developed by incorporating other information of either compounds or targets, for example, compound structural similarity ( Lo et al, 2019 ) to infer selectivity of novel compounds, even without any measured bioactivities. Alternatively, machine learning methods can be used to predict bioactivities for the compound-target pairs that have not yet been explored experimentally ( Bora et al, 2016 ; Merget et al, 2017 ; Öztürk et al, 2018 ; Thafar et al, 2019 ; Vamathevan et al, 2019 ; Bagherian et al, 2020 ; Nguyen et al, 2020 ; Schneider et al, 2020 ; Cichońska et al, 2021 ; Ye et al, 2021 ), after which the target-specific compound selectivity metric can be applied to the fully predicted compound target interaction matrix to identify selective lead compounds against any target of interest. In the general method development, we did not distinguish between the on- and off-targets, or penalized targets that may lead to adverse effects in clinical applications, but such factors could be later incorporated into the general selectivity scoring approach when applied to a particular disease or cellular context, similar to the KInhibition Selectivity Score ( Bello and Gujral, 2018 ), but this will require careful distinction between the therapeutic and toxicity-related targets.…”